SureTrader Nadex Advertisement Interactive Brokers Advertisement SureTrader
Home > Boards > US Listed > Biotechs >

Bio-Path Holdings Inc. (BPTH)

BPTH RSS Feed
Add BPTH Price Alert      Hide Sticky   Hide Intro
Moderator: SJSTOCKSHARK
Search This Board: 
Last Post: 5/25/2017 12:31:03 AM - Followers: 37 - Board type: Free - Posts Today: 1

Bio-path Holdings Inc.

Company Description:

Bio-Path is engaged in the business of financing and commercializing novel cancer therapeutics acquired from MD Anderson Cancer Center. Their first Antisense drug BP-1001 has completed a combination (with LDAC) safety phase  8 cohort for treatment of AML. No toxicity was seen. 5 out of 6 patients acheived at least partial remission. 50% had total remission! The company has completed the review by the FDA for this drug to begin phase II. The patient dosing has begun at trials which will occur at up to 10 sites or more, including MD Anderson, Baylor, New Jersey Hematology Oncolo
gy Associates, West Virginia University and University of Kansas.

Bio-Path Holdings is focused on antisense drugs which work at a cellular level to interrupt protein production by the diseased cell. The lead drug is BP1001 targeting the Grb-2 protein. Several years ago Gilead attempted to produce viable antisense drugs unsuccessfully because of high toxicity caused by their cationic (positively charged) liposome delivery system. Bio Path Holdings' delivery system is a small molecule neutral liposome system. Through the 8 cohort of phase 1 (treating different types of leukemia) there has been absolutely no toxicity. Testing performed by Bio Path demonstrates an uptake of the drug at a cellular level. The pErk results demonstrate not only a 50+% knockdown of the target protein but shows the pathway was shut down validating our delivery system. With the completion of the combination safety trials with LDAC and FDA approval, phase 2 has begun and is accepting patients.  This trial will occur at several sites. The purpose of phase 2 will be to test the effectiveness of the drug. The company may explore FDA accelerated status after testing is complete on 19 additional patients which is expected to occur in mid 2017. A CML combination drug safety study for BP1001 is also expected to be completed by mid 2017.
 
Bio-Path Holdings will also begin phase 1 testing of their antisense drug BP1001 on certain types of breast cancer which the date have been resistant to treatment.  Additionally, BPTH is initiating development of a second drug BP1002 targeting Bcl-2 for Follicular Lymphoma. An IND for BP1002 is projected for early 2017.

The company has entered into a sponsored research agreement with the University of Texas Southwestern Medical Center to evaluate BPTH's pipeline for efficacy in down-regulating the immune response using systemic lupus erythematosus (SLE) as a model. Bio-Path has entered into a sponsored research agreement with Thomas Jefferson University to investigate DNAbilize™ antisense DNA technology for the development of a brain cancer immunotherapy that works by activating the patient’s own immune system to fight their cancer. Also, BPTH has entered into a sponsored research agreement with MD Anderson to evaluate the ability of its pipeline to modulate pancreatic cancer.


http://www.biopathholdings.com


While antisense drugs fell out of favor following Gilead's failed efforts there is now renewed interest.  Ionis established partnerships with Biogen Idec and GlaxoSmithKline for their antisense technology. If Bio-Path holdings proves the validity of their delivery system, I would expect similar partnerships.

This link to the company website describes their novel delivery technology:


http://biopathholdings.com/technology/


The company was founded on the technology from M.D. Anderson Cancer Center at the University of Texas in Houston. M.D. Anderson was the largest shareholder. After raising an additional 10 million dollars the company has $11+ million in cash. These funds should allow the company to start phase II testing of their antisense drug BP1001 on leukemia and begin phase I testing for breast cancer. The company has an "at the market" credit facility in place with Cantor Fitzgerald to raise another $25 million.

 
Bio-Path Holdings do not manufacture their drug but uses contractors. Once the efficacy of BP1001 is established, I would anticipate a manufacturing partnership will occur. The CEO says the company has now ramped up their structure as they are a phase 2 developmental company.
 
BPTH is traded on the NASDAQ.

Here is the link to the peer paper prepared by their experts:


http://www.abstractsonline.com/pp8/#!/4292/presentation/2610

http://www.biopathholdings.com/pdf/PeerExpertOpinion20150107.pdf

Analyst target price: Maxim $2, Rodman & Renshaw $5, HC Wainwright a buy with a $5.00 target.

Zack's upgraded rating now equals 2 or buy.

                        
 
 
 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BPTH
Current Price
Volume:
Bid Ask Day's Range
PostSubject
#2681   I had heard there were only 11 currently iloveu2 05/25/17 12:31:03 AM
#2680   This stock is priced like a company close SJSTOCKSHARK 05/24/17 04:26:53 PM
#2679   Dang it, I wish I knew that sooner. dmoffat 05/24/17 03:24:20 PM
#2678   Strange that anyone is buying this knowing it iloveu2 05/24/17 01:05:08 PM
#2677   Let me clarify, I don't think he is Pat Torney 05/23/17 12:49:28 PM
#2676   Pat, I agree with you. Peter is just PStates 05/23/17 09:29:37 AM
#2675   Moffat, Is it because they got a substantial SJSTOCKSHARK 05/22/17 03:51:57 PM
#2674   The only comfort I can give myself is dmoffat 05/22/17 03:22:36 PM
#2673   GP, I continue to add at these prices SJSTOCKSHARK 05/22/17 03:14:28 PM
#2672   No, SJ I am not a buyer today. Gpheart2016 05/22/17 02:45:35 PM
#2671   Pat, Good point! That explains the deal. Currying SJSTOCKSHARK 05/22/17 01:53:26 PM
#2670   I'm not surprised at all. Peter would Pat Torney 05/22/17 01:27:42 PM
#2669   I am speechless, other than to say that dmoffat 05/22/17 12:42:28 PM
#2668   UNBELIAVABLE! I guess I was totally wrong that PN SJSTOCKSHARK 05/22/17 11:47:15 AM
#2667   WOW, down 11% today. How many days of Gpheart2016 05/22/17 11:41:21 AM
#2666   Thanks SJ , I saw this other day too simple 05/19/17 07:38:12 PM
#2665   This info. was sent to me by another SJSTOCKSHARK 05/19/17 04:58:15 PM
#2664   iluv, 10% from here is peanuts (5 cents SJSTOCKSHARK 05/18/17 07:49:14 PM
#2663   That is so nice of Peter to wait dmoffat 05/18/17 05:21:09 PM
#2662   Because when they have to raise funds, they iloveu2 05/18/17 03:43:38 PM
#2661   This PPS decline is arguably a Russell pre-reconstitution SJSTOCKSHARK 05/18/17 02:53:38 PM
#2660   1 month chart is horrific. 2 month docprep 05/17/17 06:44:11 PM
#2659   Here come the 40s and the sad thing iloveu2 05/17/17 06:24:18 PM
#2658   I'm currently holding about 30% of my initial BPTH2008 05/17/17 04:48:27 PM
#2657   I have enough and have to agree with too simple 05/17/17 02:46:40 PM
#2656   I think I have given up on this dmoffat 05/17/17 11:26:03 AM
#2655   The Russell rankings occurred on 5/12/17. The continued SJSTOCKSHARK 05/17/17 11:21:22 AM
#2654   Wow, we have a drug and delivery system cautious optimist 05/15/17 06:48:13 PM
#2653   Ionis' antisense drug meets phase III goals. Note SJSTOCKSHARK 05/15/17 10:53:36 AM
#2652   Word, How about a claw back of shares SJSTOCKSHARK 05/11/17 10:55:33 PM
#2651   This is interesting from the the quarterly report: wordlender 05/11/17 10:21:01 PM
#2650   Tk, I agree 100%. SJSTOCKSHARK 05/11/17 09:16:27 PM
#2649   I've been silent too long. PN this Tkikdj 05/11/17 07:08:00 PM
#2648   So based on the last update, my current dmoffat 05/11/17 01:07:31 PM
#2647   Bp you took the words right out of too simple 05/11/17 12:19:11 PM
#2646   One concern I have is with the PPS BPTH2008 05/11/17 10:56:51 AM
#2645   I have to agree with I love. We Gpheart2016 05/11/17 10:52:14 AM
#2644   As expected no numbers in the stage II SJSTOCKSHARK 05/11/17 09:13:58 AM
#2643   After reading the report, I now believe low iloveu2 05/11/17 07:55:04 AM
#2642   Unless there is some information given different than iloveu2 05/10/17 08:58:48 PM
#2641   Moffat, Oooppps! Sorry I now see that the SJSTOCKSHARK 05/10/17 05:33:26 PM
#2640   These updates have been mostly repeats and never dmoffat 05/10/17 02:56:44 PM
#2639   I can't even bring myself around to listen too simple 05/10/17 01:53:24 PM
#2638   Iloveu2, what is your next prediction on the dmoffat 05/10/17 11:32:56 AM
#2637   SJ, sorry I was vague. My question was dmoffat 05/10/17 11:23:44 AM
#2636   Moffat, I am simply pointing out the market SJSTOCKSHARK 05/10/17 11:08:20 AM
#2635   How are you able to accurately predicted this? dmoffat 05/10/17 11:03:51 AM
#2634   So you're thinking there will be no run dmoffat 05/09/17 06:44:38 PM
#2633   The market appears to be approaching the BPTH SJSTOCKSHARK 05/09/17 02:57:45 PM
#2632   I certainly believed in this stock for many BULLDOZER1 05/06/17 04:18:52 PM
PostSubject